Fulcrum Therapeutics (FULC) PT Lowered to $43 at Stifel
Tweet Send to a Friend
Stifel analyst Dae Gon Ha lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $43.00 (from $45.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
